Development of a Serum Biomarker Assay That Differentiates Tumor-Associated MUC5AC (NPC-1C ANTIGEN) from Normal MUC5AC

<table>NPC-1C antibody reacts with a colorectal and pancreatic cancer-specific antigen. NPC-1C antigen secreted by serum-starved CFPAC-1 cells was used to coat a 96-well microtiter plate. Following a blocking step, 1 <i>μ</i>g/mL of NPC-1C antibody was added to the wells in the absence or presence of increasing amounts of conditioned medium from CFPAC-1 (pancreatic), LS174T (colorectal), or A549 (lung) cells to compete for NPC-1C binding to the coated antigen. The ELISA was developed by adding anti-human IgG-conjugated peroxidase reagent followed by TMB substrate.</table>

BioMed Research International

fig1

Figure 1

Figure 1: Development of a Serum Biomarker Assay That Differentiates Tumor-Associated MUC5AC (NPC-1C ANTIGEN) from Normal MUC5AC 